mRNA 1440
Alternative Names: H10N8 Antigen mRNA; H10N8 vaccine; VAL 506440Latest Information Update: 28 May 2021
At a glance
- Originator Valera LLC
- Class Antibodies; Influenza virus vaccines; RNA; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus infections
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Influenza-A-virus-infections(Prevention, In volunteers) in Germany (Parenteral)
- 16 May 2019 Phase I development in Influenza-A-virus-infections is ongoing in Germany (Moderna Therapeutics pipeline, May 2019)
- 12 May 2019 Safety and immunogenicity data from a phase I trial in Influenza-A virus infections (In volunteers, Prevention) released by Moderna Therapeutics